Perrigo announces FDA approval of store brand equivalent to Flonase

DUBLIN -  The national brand equivalent of GlaxoSmithKline's Flonase will soon be shipping to store shelves with the announcement Monday that Perrigo and its partner West-Ward Pharmaceuticals on Tuesday gained approval from the U.S. Food and Drug Administration.

"This product approval and launch demonstrates the power of Perrigo's OTC platform," stated John Hendrickson, Perrigo CEO. "Our team has made significant efforts to bring this important product to our customers and consumers in the U.S."

Flonase (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and pediatric patients 4 years of age and older. Combined store brand and national brand sales for the twelve months ending May 2016 were $343 million, Perrigo reported.